Epsilon Molecular Engineering (EME) creates proprietary cDNA display libraries for VHH and cyclic peptides using evolutionary molecular engineering and a high-throughput system that leverages next-generation sequencing, fluorescence-activated cell sorting, and AI. The company focuses on drug discovery in the medical field, developing biological and medium-sized molecular drug candidates and exploring VHH applications in cell and gene therapy. EME conducts collaborative R&D with pharmaceutical manufacturers and research institutions while also advancing an internal pipeline and early-stage development partnerships. The firm recently announced a VHH that can inhibit COVID-19 infection through collaborative research with Kitasato University and Kao Corporation. EME plans to accelerate collaborative research with pharmaceutical manufacturers and internal research using its pipeline to advance next-generation biotechnology-based drug discovery. Founded in 2016, the company aims to translate its screening and design technologies into therapeutic pharmaceuticals.

Total raised

$6M

Funding rounds

4

Latest round

Series A

Latest activity

Dec 2020